Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Key innate immune protein regulates cholesterol and influences cancer treatment resistance (opens in a new tab)

news-medical.net · 2026-11-03

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of seven claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 3 supported
  • 4 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredThe finding appeared November 2, 2026, in the Journal of Clinical Investigation.View evidenceHide evidence

Why this verdict

The supplied paper profile is abstract-depth and does not include bibliographic publication details sufficient to verify the stated publication date or Journal of Clinical Investigation appearance.

Claim 2 of 7Not coveredIn cancer cells and implanted mouse tumor models without cGAS, tumors grew significantly faster and showed heightened activation of a key regulatory pathway; restoring cGAS or LGALS3 slowed tumor growth and reduced cholesterol buildup.View evidenceHide evidence

As statedsignificantly faster

Why this verdict

The abstract-level profile supports that cGAS depletion promotes xenografted tumor growth and activates the cholesterol/PI(3,4,5)P3/mTORC2/Akt axis. However, it does not provide the quantitative/statistical basis for 'significantly faster' tumor growth, nor does it verify the specific rescue claim that restoring cGAS or LGALS3 slowed tumor growth and reduced cholesterol buildup. Those details may require full-text evidence.

1

Study evidence

Nuclear cGAS depletion causes cholesterol accumulation and elevated plasma-membrane PI(3,4,5)P3, driving increased mTORC2 activation and Akt signaling; conversely, reduced cholesterol associated with cGAS activity lowers PI(3,4,5)P3 and decreases mTORC2 activation.

“Reduced cholesterol lowers plasma membrane phosphatidylinositol [3,4,5] triphosphate [PI(3,4,5)P3] levels and decreases mTOR complex 2 (mTORC2) activation.”
2

Study evidence

cGAS depletion promotes xenografted tumor growth concomitant with activation of mTORC2/Akt signaling.

“cGAS depletion results in cholesterol accumulation and elevated PI(3,4,5)P3, driving mTORC2/Akt signaling, promoting xenografted tumor growth…”
Claim 3 of 7Not coveredcGAS-deficient cancer cells were more resistant to common chemotherapy drugs such as doxorubicin and to cholesterol-lowering agents, and reintroducing cGAS or LGALS3 reversed this resistance.View evidenceHide evidence

Why this verdict

The profile supports a resistance phenotype to DNA-damaging agents after cGAS depletion, which could be consistent with chemotherapy examples such as doxorubicin. But the abstract-level profile does not specify doxorubicin, does not mention resistance to cholesterol-lowering agents, and does not verify that reintroducing cGAS or LGALS3 reversed resistance. These particulars are not verifiable from the supplied abstract-depth profile.

1

Study evidence

cGAS depletion/deficiency confers resistance to DNA-damaging agents; this phenotype is associated with cholesterol accumulation, elevated PI(3,4,5)P3, and increased mTORC2/Akt signaling that also promotes xenograft tumor growth.

“…and conferring resistance to DNA-damaging agents.”
Claim 4 of 7Not coveredThe article says the discovery could point to therapeutic strategies that modulate cGAS transcriptional activity or target the LGALS3 pathway, with possible relevance beyond cancer.View evidenceHide evidence

Why this verdict

The paper profile provides mechanistic and animal evidence that could motivate future therapeutic speculation, and it includes non-tumor hepatic cholesterol findings that could suggest relevance beyond cancer. However, the abstract-depth profile does not directly state therapeutic strategies based on modulating cGAS transcriptional activity or targeting the LGALS3 pathway. The claim is hedged, but its translational implication is not directly verifiable at this depth.

1

Study evidence

Nuclear cGAS promotes LGALS3 transcription, which inhibits ACAA2 activity, suppresses fatty acid oxidation and acetyl-CoA production, and thereby lowers intracellular cholesterol levels.

“Mechanistically, cGAS promotes LGALS3 transcription, which inhibits ACAA2 activity to suppress fatty acid oxidation and acetyl-CoA production, thereby lowering intracellular cholesterol levels.”
2

Study evidence

cGAS depletion promotes xenografted tumor growth concomitant with activation of mTORC2/Akt signaling.

“cGAS depletion results in cholesterol accumulation and elevated PI(3,4,5)P3, driving mTORC2/Akt signaling, promoting xenografted tumor growth…”
Claim 5 of 7SupportedScientists at the University of North Carolina Lineberger Comprehensive Cancer Center discovered an unexpected role for cGAS, showing that it helps regulate cholesterol levels inside cells and influences tumor growth and treatment response.View evidenceHide evidence

Why this verdict

The abstract-level paper profile supports the central scientific framing: nuclear cGAS has an unexpected chromatin/transcriptional role, regulates cholesterol homeostasis, and cGAS depletion is linked to xenograft tumor growth and resistance to DNA-damaging agents. The profile does not independently verify the UNC affiliation, but the scientific claim as framed is supported.

1

Study evidence

A genome-wide map of nuclear cGAS chromatin localization in human cells was produced using CUT&RUN.

“Here, we present a genome-wide map of cGAS chromatin localization in human cells”
2

Study evidence

Integrated CUT&RUN, RNA-seq, and metabolomics analyses indicate that nuclear cGAS transcriptionally regulates cholesterol homeostasis.

“Integrated CUT&RUN, RNA-seq, and metabolomics analyses reveal that cGAS transcriptionally regulates cholesterol homeostasis.”
Claim 6 of 7SupportedThe article says cGAS can act in the nucleus, where it binds specific genome regions and helps control which genes are turned on or off, including increasing production of LGALS3.View evidenceHide evidence

Why this verdict

The profile states that the paper maps cGAS chromatin localization in human cells, reports recruitment to chromatin, and links nuclear cGAS to transcriptional regulation, including cGAS-dependent LGALS3 transcription. The story’s hedged framing is consistent with the abstract-level evidence.

1

Study evidence

A genome-wide map of nuclear cGAS chromatin localization in human cells was produced using CUT&RUN.

“Here, we present a genome-wide map of cGAS chromatin localization in human cells”
2

Study evidence

Integrated CUT&RUN, RNA-seq, and metabolomics analyses indicate that nuclear cGAS transcriptionally regulates cholesterol homeostasis.

“Integrated CUT&RUN, RNA-seq, and metabolomics analyses reveal that cGAS transcriptionally regulates cholesterol homeostasis.”
Claim 7 of 7SupportedAccording to the story, cGAS increases LGALS3, which reduces acetyl-CoA availability, lowers cholesterol production, and when cGAS is missing the opposite occurs, leading to excess cholesterol and activation of a growth-promoting pathway.View evidenceHide evidence

Why this verdict

The profile explicitly reports the mechanistic chain: cGAS promotes LGALS3 transcription, LGALS3 inhibits ACAA2 activity, fatty-acid oxidation and acetyl-CoA production are suppressed, intracellular cholesterol is lowered, and cGAS depletion causes cholesterol accumulation with elevated PI(3,4,5)P3 and mTORC2/Akt signaling. The story’s 'growth-promoting pathway' language corresponds to the mTORC2/Akt pathway in the profile.

1

Study evidence

Nuclear cGAS promotes LGALS3 transcription, which inhibits ACAA2 activity, suppresses fatty acid oxidation and acetyl-CoA production, and thereby lowers intracellular cholesterol levels.

“Mechanistically, cGAS promotes LGALS3 transcription, which inhibits ACAA2 activity to suppress fatty acid oxidation and acetyl-CoA production, thereby lowering intracellular cholesterol levels.”
2

Study evidence

Nuclear cGAS depletion causes cholesterol accumulation and elevated plasma-membrane PI(3,4,5)P3, driving increased mTORC2 activation and Akt signaling; conversely, reduced cholesterol associated with cGAS activity lowers PI(3,4,5)P3 and decreases mTORC2 activation.

“Reduced cholesterol lowers plasma membrane phosphatidylinositol [3,4,5] triphosphate [PI(3,4,5)P3] levels and decreases mTOR complex 2 (mTORC2) activation.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • In vivo non-tumor physiology: elevated hepatic cholesterol in cGas-/- mice reversed by Akt inhibition but not STING inhibition, with minimal lung effects

    The story’s supplied claims mention possible relevance beyond cancer but do not reflect the specific secondary in vivo physiological evidence: hepatic cholesterol changes in cGas-/- mice, reversal by Akt inhibition rather than STING inhibition, and minimal lung physiology effects.

    From In vivo knockout with pharmacologic intervention

6 things the story did carry across
  • Nuclear cGAS chromatin localization and transcriptional role
  • cGAS-dependent transcriptional/metabolic regulation of cholesterol homeostasis via LGALS3 and acetyl-CoA metabolism
  • PI(3,4,5)P3 and mTORC2/Akt signaling as the downstream growth pathway
  • Xenograft tumor growth consequences of cGAS depletion
  • Therapy resistance to DNA-damaging agents after cGAS depletion
  • Translational limitation: findings are from mechanistic cell and animal models rather than clinical patient outcomes
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

7

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroMap nuclear cGAS chromatin localization in human cells and define how it is recruited to chromatin (via AP-1 transcription factors and a putative cGAS transactivation domain).CUT&RUN-based chromatin mapping and TF-association analysisExpand

In plain English

The authors report a genome-wide map of nuclear cGAS chromatin localization in human cells using CUT&RUN chromatin profiling and infer that cGAS is recruited to chromatin by AP-1 transcription factors via a putative cGAS transactivation domain; CUT&RUN data were integrated with RNA-seq and metabolomics to link cGAS chromatin occupancy to transcriptional and metabolic outcomes.

Key findings

  • A genome-wide map of nuclear cGAS chromatin localization in human cells was produced using CUT&RUN.
  • cGAS chromatin binding occurs beyond previously described nucleosome tethering constraints.
“Here, we present a genome-wide map of cGAS chromatin localization in human cells”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroDefine the transcriptional/metabolic program controlled by nuclear cGAS, linking cGAS to cholesterol homeostasis via LGALS3 and downstream fatty-acid oxidation/acetyl-CoA production and mTORC2/Akt signaling.in vitroExpand

In plain English

Integrated transcriptomic and metabolomic profiling (reported in the abstract) indicates that nuclear cGAS controls a transcriptional program that impacts cellular cholesterol homeostasis: RNA-seq implicates cGAS-dependent induction of LGALS3, and metabolomics/lipidomics show changes consistent with reduced fatty-acid oxidation, lower acetyl-CoA production, and decreased intracellular cholesterol when cGAS is present, with cholesterol accumulation on cGAS depletion. These multi-omics data underpin the claim that nuclear cGAS links transcriptional regulation to lipid/cholesterol metabolism.

Key findings

  • Integrated CUT&RUN, RNA-seq, and metabolomics analyses indicate that nuclear cGAS transcriptionally regulates cholesterol homeostasis.
  • RNA-seq identified LGALS3 as a cGAS-dependent transcriptional target implicated in the pathway linking cGAS to lipid metabolism.
“Integrated CUT&RUN, RNA-seq, and metabolomics analyses reveal that cGAS transcriptionally regulates cholesterol homeostasis.”
What this piece can’t prove
  • This appraisal unit covers global profiling (RNA-seq and metabolomics) and their integration; detailed biochemical/enzymatic mechanism validation (e.g., direct assays of ACAA2 activity) is outside the scope of this unit.

3 further details could not be confirmed from the summary.

3in vitroDefine the transcriptional/metabolic program controlled by nuclear cGAS, linking cGAS to cholesterol homeostasis via LGALS3 and downstream fatty-acid oxidation/acetyl-CoA production and mTORC2/Akt signaling.in vitroExpand

In plain English

The paper reports that nuclear cGAS drives transcription of LGALS3, and LGALS3 in turn inhibits ACAA2 activity; this reduces fatty acid oxidation and acetyl-CoA production, leading to decreased intracellular cholesterol levels.

Key findings

  • Nuclear cGAS promotes LGALS3 transcription, which inhibits ACAA2 activity, suppresses fatty acid oxidation and acetyl-CoA production, and thereby lowers intracellular cholesterol levels.
“Mechanistically, cGAS promotes LGALS3 transcription, which inhibits ACAA2 activity to suppress fatty acid oxidation and acetyl-CoA production, thereby lowering intracellular cholesterol levels.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vitroDefine the transcriptional/metabolic program controlled by nuclear cGAS, linking cGAS to cholesterol homeostasis via LGALS3 and downstream fatty-acid oxidation/acetyl-CoA production and mTORC2/Akt signaling.in vitroExpand

In plain English

Paper reports that nuclear cGAS controls cholesterol homeostasis such that reduced nuclear cGAS activity lowers intracellular cholesterol, which reduces plasma-membrane PI(3,4,5)P3 and decreases mTORC2 activation; conversely, cGAS depletion causes cholesterol accumulation, elevated PI(3,4,5)P3, and increased mTORC2/Akt signaling. Findings are reported from experiments that assessed PI(3,4,5)P3 levels and mTORC2/Akt activation after cGAS perturbation.

Key findings

  • Nuclear cGAS depletion causes cholesterol accumulation and elevated plasma-membrane PI(3,4,5)P3, driving increased mTORC2 activation and Akt signaling; conversely, reduced cholesterol associated with cGAS activity lowers PI(3,4,5)P3 and decreases mTORC2 activation.
“Reduced cholesterol lowers plasma membrane phosphatidylinositol [3,4,5] triphosphate [PI(3,4,5)P3] levels and decreases mTOR complex 2 (mTORC2) activation.”
What this piece can’t prove
  • Abstract does not report quantitative effect sizes or statistical robustness for PI(3,4,5)P3 and mTORC2/Akt changes.
  • It is not specified whether PI(3,4,5)P3 measurements were cell-type–specific or how membrane localization was assessed in the reported experiments.

1 further detail could not be confirmed from the summary.

5in vivo animalEstablish functional consequences of cGAS loss on tumor growth and therapy response (DNA-damaging agents), including xenograft growth and resistance phenotypes.in vivo xenograft model and in vivo genetic knockoutExpand

In plain English

Abstract-reported in vivo xenograft experiments: depletion/deficiency of cGAS is associated with cholesterol accumulation, increased PI(3,4,5)P3, activation of mTORC2/Akt signaling, promotion of xenografted tumor growth, and resistance to DNA-damaging agents.

Key findings

  • cGAS depletion promotes xenografted tumor growth concomitant with activation of mTORC2/Akt signaling.
  • cGAS depletion confers resistance to DNA-damaging agents.
“cGAS depletion results in cholesterol accumulation and elevated PI(3,4,5)P3, driving mTORC2/Akt signaling, promoting xenografted tumor growth…”
What this piece can’t prove
  • Unclear whether therapy-resistance observations derive from the same in vivo xenograft experiments or from separate in vitro/in vivo assays.

3 further details could not be confirmed from the summary.

6in vitroEstablish functional consequences of cGAS loss on tumor growth and therapy response (DNA-damaging agents), including xenograft growth and resistance phenotypes.in vitro drug-response assays with genetic cGAS depletion (and separate xenograft growth assays)Expand

In plain English

The abstract reports that loss or depletion of cGAS leads to resistance to DNA-damaging agents. This phenotype is presented alongside mechanistic data linking cGAS deficiency to cholesterol accumulation, elevated PI(3,4,5)P3, and activation of mTORC2/Akt signaling; the authors state that these signaling changes promote tumor growth and confer resistance to DNA-damaging therapies.

Key findings

  • cGAS depletion/deficiency confers resistance to DNA-damaging agents; this phenotype is associated with cholesterol accumulation, elevated PI(3,4,5)P3, and increased mTORC2/Akt signaling that also promotes xenograft tumor growth.
“…and conferring resistance to DNA-damaging agents.”
What this piece can’t prove
  • Abstract-only reporting: experimental details required to evaluate the therapy-response experiments (specific DNA-damaging agents, concentrations/doses, treatment schedules, assay types, replicates, and statistical measures) are not provided.
  • Unclear experimental context: the abstract does not specify which cell lines or models were used for the therapy-resistance assays, nor whether resistance was measured in vitro, in xenografts, or both.

2 further details could not be confirmed from the summary.

7in vivo animalValidate the in vivo physiological relevance of cGAS-dependent cholesterol regulation in mice (hepatic cholesterol changes; pharmacologic rescue by Akt inhibition but not STING inhibition; minimal lung effects).In vivo knockout with pharmacologic interventionExpand

In plain English

Abstract-level in vivo evidence: cGas-/- mice show elevated hepatic cholesterol that was largely reversed by Akt inhibition but not by STING inhibition; cGAS deficiency produced minimal effects on lung physiology.

Key findings

  • cGas-/- mice showed elevated hepatic cholesterol levels.
  • Pharmacologic Akt inhibition largely reversed the elevated hepatic cholesterol in cGas-/- mice, whereas STING inhibition did not reverse it.
“In vivo, the elevated hepatic cholesterol levels observed in cGas-/- mice were largely reversed by inhibition of Akt but not STING, whereas cGAS deficiency had minimal effects on lung physiology.”
What this piece can’t prove
  • Summary is based solely on abstract text; full experimental details, methods, sample sizes, and statistical analyses are not available here.
  • Key methodological details missing in abstract: mouse strain/background, sex and age distribution, cohort sizes, exact inhibitor identities, doses, administration routes and schedules, and assay methodologies for cholesterol and lung physiology.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 39 candidate papers

And 33 more candidates considered.